Other RCC applications for novel tracers remain in developmental stages, but may prove useful in the future: 124I-girentuximab, targeting carbonic anhydrase (CA) IX (suggestive for clear cell RCC) [62], and prostate-specific membrane antigen (PSMA), with its epithelial membrane target [63]. This evidence concerns the gene CA9 and renal cell carcinoma.